CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
inhaled carbon monoxide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01214187
NCT01214187Phase 2Completed
CompareCT.gov

Phase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary Fibrosis

Brigham and Women's Hospital·interventional·Posted Oct 4, 2010·Updated Jun 14, 2017

In Brief

A Phase 2 clinical trial evaluating inhaled carbon monoxide and Oxygen for Idiopathic Pulmonary Fibrosis. Completed, enrolled 58 participants across 8 sites.

Detailed Summary

The purpose of this study is to determine whether low concentration inhaled carbon monoxide is effective in treating idiopathic pulmonary fibrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), University of California, San Francisco, University of Chicago, University of Illinois at Chicago, University of Michigan, Columbia University, Tulane University, University of Washington

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 4, 2010
Enrollment StartJul 1, 2011
Primary CompletionOct 1, 2014
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.7 years ago

Interventions

inhaled carbon monoxidedrug

The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.

Oxygenother

Room air oxygen concentrations will be administered as placebo